MDT · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

Medtronic plc · 2026-09-03 · Importance 54 · Surprise 40 · No source text

Total net sales increased 14% year over year to $9.756 billion for the three months ended July 31, 2026, from $8.578 billion, including an estimated $570 million benefit from the 53rd fiscal week and favorable foreign-currency impacts. Cardiovascular sales rose 20% to $3.927 billion, Neuroscience increased 10% to $2.678 billion, and Medical Surgical increased 10% to $2.279 billion. Cardiovascular growth was led by Electrophysiology Therapies, up 30% on pulsed-field ablation and cardiac rhythm products, while Interventional Cardiology Therapies increased 7%, CardioVascular Surgery increased 9%, and Peripheral Vascular Health increased 12%. Diabetes sales increased 17% to $843 million, driven by the U.S. launch of MiniMed Flex with Simplera Sync and international adoption of the MiniMed 780G AID system.

Key facts

• Total net sales for the three months ended July 31, 2026 were $9,756 million compared to $8,578 million for the three months ended July 25, 2025. source
• Reportable segment net sales for the three months ended July 31, 2026 were $8,884 million compared to $7,785 million for the three months ended July 25, 2025. source
• Medical Surgical net sales for the three months ended July 31, 2026 were $2,279 million compared to $2,073 million for the three months ended July 25, 2025, an increase of 10 percent. source
• The extra week had an estimated benefit to reported growth of approximately $570 million for the three months ended July 31, 2026. source
• Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in the three months ended July 31, 2026 results. source

Impact estimates